<DOC>
	<DOCNO>NCT00045994</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ALT-711 treatment isolate systolic hypertension formal study patient leave ventricular hypertrophy . Eligible patient randomize double-blind treatment daily 6 month oral ALT-711 ( 210 mg ) placebo .</brief_summary>
	<brief_title>The SILVER Study : Systolic Hypertension Interaction With Left Ventricular Remodeling</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Ventricular Remodeling</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<criteria>Inclusion Criteria Men woman least 50 year age . Screening diagnosis isolate systolic hypertension , define systolic blood pressure &gt; 150 mm Hg diastolic blood pressure &lt; 90 mm Hg ( office blood pressure measurement ) systolic blood pressure &gt; 140 mm Hg ( measure 24hour ambulatory blood pressure monitoringmean daytime value ) . Baseline systolic blood pressure &gt; 150 mm Hg diastolic blood pressure &lt; 90 mm Hg ( office blood pressure measurement ) . Patients leave ventricular hypertrophy ( LVH ) determine limited echocardiography LVH ( i.e. , wall thickness &gt; 1.2 cm ) . Patient complete inform consent . Exclusion Criteria Patient &lt; 50 year age . Patients antihypertensive therapy change dose last 1 month prior entry study . Hb A1c &gt; 9 % . Serum creatinine &gt; 1.7mg/dL . History ketoacidosis uncontrolled diabetes within last 2 year . History congestive heart failure . History stroke , sequelae transient ischemic attack , reversible ischemic neurologic defect , stroke , within last 12 month . History acute myocardial infarction within 6 month prior entry study . Any significant ECG abnormality , include second degree AVblock complete AVblock . Any known significant arrhythmia include atrial flutter , ventricular tachycardia , WPWsyndrome . Any hemodynamically significant valvular heart disease . Any significant systemic illness medical condition could lead difficulty comply protocol . Screening Baseline liver function test SGOT and/or SGPT &gt; 2.0 time upper limit central laboratory normal range . Use systemic and/or inhale corticosteroid ( exclude topical corticosteroid ) . Any additional condition ( ) , investigator 's opinion would prohibit patient complete study , best interest patient . Use investigational drug within 30 day prior screen . Previous exposure ALT711 . Known seropositivity HIV hepatitis C , presence hepatitis B surface antigen . Pregnancy active breastfeeding . Female patient childbearing potential ( postmenopausal least 5 year surgically sterilize ) must agree become pregnant duration study . Specifically , must agree use appropriate contraceptive regimen . Acceptable regimen include abstinence , systemic hormone , intrauterine device barrier method , cervical cap , male female condom , diaphragm concomitant intravaginal spermicide . A barrier method must use without failure least 1 year immediately precede entry study . Positive drug screen . Necessity use tobacco nicotinecontaining product , consume caffeine containing beverage and/or food , and/or alcohol midnight prior clinic visit day , evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>cardiovascular</keyword>
	<keyword>age</keyword>
	<keyword>antihypertensive agents/therapeutic use</keyword>
	<keyword>hypertension/*drug therapy</keyword>
	<keyword>blood pressure</keyword>
</DOC>